Literature DB >> 35544160

Preliminary phase 1 results from an HIV vaccine candidate trial.

Priya Venkatesan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 35544160     DOI： 10.1016/S2666-5247(21)00042-2

Source DB:  PubMed          Journal:  Lancet Microbe        ISSN： 2666-5247


× No keyword cloud information.
  6 in total

Review 1.  Antibodies to combat viral infections: development strategies and progress.

Authors:  Giuseppe Pantaleo; Bruno Correia; Craig Fenwick; Victor S Joo; Laurent Perez
Journal:  Nat Rev Drug Discov       Date:  2022-06-20       Impact factor: 112.288

Review 2.  Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.

Authors:  Zekun Mu; Barton F Haynes; Derek W Cain
Journal:  Curr Opin Virol       Date:  2021-11-04       Impact factor: 7.121

Review 3.  The Current Landscape of mRNA Vaccines Against Viruses and Cancer-A Mini Review.

Authors:  Reese Jalal Ladak; Alexander J He; Yu-Hsun Huang; Yu Ding
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

Review 4.  Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic.

Authors:  Samagra Jain; Abhijeet Venkataraman; Marissa E Wechsler; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2021-10-09       Impact factor: 17.873

Review 5.  Leveraging lessons learned from the COVID-19 pandemic for HIV.

Authors:  Thomas Calder; Tina Tong; Dale J Hu; Jerome H Kim; Karen L Kotloff; Richard A Koup; Mary A Marovich; M Juliana McElrath; Sarah W Read; Merlin L Robb; Philip O Renzullo; M Patricia D'Souza
Journal:  Commun Med (Lond)       Date:  2022-08-29

6.  Recent Updates on mRNA Vaccines.

Authors:  Emily Sydow; Abu Salim Mustafa; Asma Hanif; Javed Tunio; Shumaila Nida Muhammad Hanif
Journal:  Vaccines (Basel)       Date:  2022-07-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.